ClinicalTrials.gov
ClinicalTrials.gov Menu

Electronic Cigarettes and Reactivity to Smoking Cues

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01782599
Recruitment Status : Recruiting
First Posted : February 4, 2013
Last Update Posted : April 19, 2018
Sponsor:
Information provided by (Responsible Party):
Amy C. Janes, Mclean Hospital

Brief Summary:
The purpose of this study is to determine whether electronic cigarettes can reduce reactivity to smoking-related cues.

Condition or disease Intervention/treatment Phase
Nicotine Dependence Other: Dual nicotine patch and electronic cigarette Not Applicable

Detailed Description:
Tobacco-related illness causes over 5 million deaths per year in the developed world, and most currently available smoking cessation treatments do not effectively enhance long-term cessation outcomes. Reactivity to smoking cues is one factor associated with relapse vulnerability, which is untreated by cessation aids such as NRT. Combining treatments, which ameliorate both pharmacological nicotine withdrawal and reduce smoking cue reactivity, may enhance smoking cessation success. During this study we will test whether combining NRT with non-nicotine containing electronic cigarettes (e-cigarettes) effectively reduces reactivity to smoking cues. The only source of nicotine participants will receive during the study will come from NRT. We will use e-cigarettes that provide no nicotine, yet may provide a similar experience to smoking as e-cigarettes taste and feel similar to a regular cigarette. However, since nicotine delivery is not associated with the act of smoking the reinforcing effects associated with smoking behavior may be reduced. Reactivity to smoking cues will be assessed using a battery of measures including: self-report, behavioral, and neuroimaging.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Electronic Cigarettes and Reactivity to Smoking Cues
Study Start Date : January 2013
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: E-Cigarettes Smoking
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Dual nicotine patch and electronic cigarette
Nicotine patch and the electronic cigarette will be administered.
Other: Dual nicotine patch and electronic cigarette



Primary Outcome Measures :
  1. Reduction in Cue Reactivity [ Time Frame: 2 weeks after use ]
    Outcomes will be measured using a battery of self-report, neuroimagning, and behavioral measures of cue-reactivity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide written informed consent.
  2. Be aged 18-45.
  3. Report smoking cigarettes daily in the past 6 months.
  4. Have expired breath CO indicative of regular smoking.
  5. Have a score greater than 0 on the FTND.
  6. Be willing to use Nicotine Replacement Therapy (NRT) and the e-cigarette for a period of 2 to 3 weeks.
  7. Speak and read English.
  8. Pass an MRI safety screen and meet inclusion criteria for MRI scans.

Exclusion Criteria:

  1. Be pregnant (measured via urinalysis).
  2. Meet current abuse or dependence criteria for any substance other than nicotine or caffeine (measured via the SCID-IV-TR).
  3. Produce a positive urine screen for drugs of abuse or alcohol at the fMRI scan visits.
  4. Meet DSM-IV criteria for major depressive episode in the past six months, lifetime DSM-IV diagnosis of organic mental disorder, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder or psychotic disorders not elsewhere classified (measured via the SCID-IV-TR).
  5. Be currently suicidal as assessed by DSM-IV-TR and the Beck Depression Inventory.
  6. Current use of medications or any history of a medical condition that might affect the central nervous system at the time of scanning including: Abnormal structural MRI, or a history of head trauma or injury causing loss of consciousness lasting longer than 3 minutes or associated with skull fracture or intracranial bleeding or who had irremovable magnetically active objects on or within their body, history of epilepsy, current use of a beta-blocker or prescription analgesic/anxiolytic. (assessed by self-report).
  7. MRI exclusion criteria. (additional information outlined in the "protection of human subjects" section).
  8. History of claustrophobia.
  9. History of propylene glycol sensitivity/allergy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01782599


Contacts
Contact: Maya Zegel, BA 617-855-3682 mzegel@mclean.harvard.edu

Locations
United States, Massachusetts
Mclean Hospital Imaging Center Recruiting
Belmont, Massachusetts, United States, 02478
Contact: Maya Zegel, BA    617-855-3682      
Principal Investigator: Amy C Janes, PhD         
Sponsors and Collaborators
Mclean Hospital
Investigators
Principal Investigator: Amy C Janes, PhD Mclean Hospital

Publications:
Responsible Party: Amy C. Janes, Assistant Professor/Associate Neuroscientist, Mclean Hospital
ClinicalTrials.gov Identifier: NCT01782599     History of Changes
Other Study ID Numbers: E-cigarettes and Cues
First Posted: February 4, 2013    Key Record Dates
Last Update Posted: April 19, 2018
Last Verified: April 2018

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action